Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | AHCY | P23526 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 3/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366274 | 1.00 | ADORA2A (0.54) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL99603 | 0.87 | AHCY (0.64) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL6363452 | 0.87 | AHCY (0.64) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL3860366 | 0.84 | CCNE1 (0.51) | ADORA2AADORA1AHCY | |
| SCHEMBL8620522 | 0.84 | CCNE1 (0.51) | ADORA2AADORA1AHCY | |
| SCHEMBL9189761 | 0.82 | ADORA2A (0.55) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL384145 | 0.82 | CYP3A4 (0.72) | ADORA2AADORA1AHCYALDH1A1CYP3A4 | |
| SCHEMBL9190527 | 0.82 | CYP3A4 (0.72) | ADORA2AADORA1AHCYALDH1A1CYP3A4 | |
| SCHEMBL2928584 | 0.82 | CYP3A4 (0.72) | ADORA2AADORA1AHCYALDH1A1CYP3A4 | |
| SCHEMBL608687 | 0.82 | CYP3A4 (0.68) | ADORA2AADORA1AHCYALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12397058-B2 | Metabolically stable prodrugs | TSRL, INC. (US) | 2025-08-26 | — | — | US | claimed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | claimed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | claimed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| EP-0533833-B1 | PHOSPHOROUS PRODUGS | GLAZIER ARNOLD (US) | 1995-12-20 | — | — | EP | claimed |
| JP-6206888-A | — | — | None | — | — | JP | disclosed |
| US-12397058-B2 | Metabolically stable prodrugs | TSRL, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12378306-B2 | Anti-fungal VHH antibodies | Biotalys NV (BE) | 2025-08-05 | — | — | US | disclosed |
| WO-2025133390-A1 | ANTI-FUNGAL VHH ANTIBODIES | Biotalys NV (BE) | 2025-06-26 | — | — | WO | disclosed |
| US-5733896-A | VIRICIDE FOR RETROVIRUS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1998-03-31 | — | — | US | disclosed |
| EP-0454427-B1 | Antiretroviral bases | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1995-12-06 | — | — | EP | disclosed |
| JP-H06206888-A | N-(3-FLUORO-2-PHOSPHONYLMETHOXYPROPYL) DERIVATIVE OF PURINE AND PYRIMIDINE HETEROCYCLIC BASES, ITS PREPARATION AND USE | AKAD VED CESKE REPUBLIKY | 1994-07-26 | — | — | JP | disclosed |
| EP-0454427-A1 | Antiretroviral bases | Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (CZ) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | ADORA2A 128/4885ADORA1 270/4885AHCY 1461/4885 |
| US-12397058-B2 | Metabolically stable prodrugs | CES1, CES2, CYP2S1 | ADORA2A 787/4885ADORA1 731/4885AHCY 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.